EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa
Through the agreement, Abdul Latif Jameel Health will become EQRxs regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.
- Through the agreement, Abdul Latif Jameel Health will become EQRxs regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.
- Its our joint mission with EQRx to change that, a mission that is aligned with the values of the Jameel Family.
- Aumolertinib is a novel, irreversible EGFR-TKI that selectively inhibits both EGFR sensitizing and resistance mutations with high selectivity over wild-type EGFR.
- EQRx and Remaking Medicine are trademarks of EQRx, Inc.
1World Health Organization, International Agency for Research on Cancer.